ESALY - Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi | Benzinga
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD).
Leqembi is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of Aβ.
Leqembi is the first and only approved treatment shown to reduce the disease progression rate ...